 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
||
 |
 |
 |
|
|||||||
 |
|
|||||||||
 |
|
|||||||||
Alert Number 124
Date: September 7, 2024
I am pleased to report an interesting clinical trial will soon be open to CLL patients. This immunotherapy approach has the potential for very low toxicity and good efficacy, since it is based on using the body’s own defenses to fight cancer.
T-cells collected from each patient are grown into large armies, activated and targeted to kill only cells with the CD-20 marker. These killer T-cells (CTLs) are then infused back into the patient, to clean-up last traces of CLL (minimum residual disease or MRD) left after more traditional treatment. This innovative approach is the basis for a Phase I clinical trial at the Fred Hutchinson Cancer Research Center in Seattle. I am particularly impressed by their targeting capability. It is an important new wrinkle in the development of cancer therapies based on T-cell technology. As we know, the CD20 marker is carried by all CLL cells, and more over it is limited only to mature B-cells. No other cell line carries this marker. Efficient killing of only the cancer cells and the sparing of healthy tissue is at the heart of improving cancer therapies, the key to getting better bang for the buck.
This trial will start recruiting patients very shortly. You can expect the formal announcement in the next few days. Consider this an advance notice for Topics Alert subscribers. You can read our review of this latest evolution in using CTLs in Autologous CD-20 Targeted T-Cell Therapy. We describe the technology, the pros and cons of this early phase clinical trial - and contact information in case you think you may be eligible to participate in this trial.
Be well,
Chaya
____
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———
